Archived explainer. For the current picture see today's GRAL page.
GRAIL INC EQUITY Equity (GRAL) is up +15.38% in the latest session. Our newswire has captured 4 stories on GRAL across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 71/100).
GRAIL (GRAL) surged 15.38% to $125.21 on Wednesday, setting a new 52-week high. The rally followed a favorable outcome from an FDA advisory panel, which endorsed the company’s Galleri multi-cancer early detection blood test. The panel voted that there is reasonable evidence supporting the test’s effectiveness and that its benefits outweigh its risks for the proposed use. The decision removed a key regulatory hurdle and signaled progress toward potential commercialization.
GRAIL’s stock had been on a trading halt on Wednesday ahead of the FDA panel meeting. The company’s Galleri test, which aims to detect multiple types of cancer from a single blood sample, received a 6-4 vote from advisers on its effectiveness and a 7-2 vote on the benefit-risk profile. This endorsement is a major milestone for GRAIL, which has been investing heavily in research and development to bring the test to market. The stock had already gained 34% on Monday after the FDA released briefing documents that highlighted no significant safety concerns.
The positive outcome has positioned GRAIL among the top-performing health care stocks this month. It is one of five smaller health care names with market caps above $100 million that have outperformed Moderna (MRNA), which is set to be the second-largest gainer in the S&P 500 for September.
Over the past eight trading sessions, GRAL has risen 53.2% from $75.89 to $116.28. The stock’s beta of 3.25 indicates it is highly volatile relative to the broader market. With a market cap of $4.8 billion and a net margin of -236.9%, GRAIL remains unprofitable but has shown revenue growth of 23.1% in the trailing twelve months. The recent surge has pushed the stock to a new 52-week high, with 45 fresh 52-week highs recorded on September 24.
GRAIL’s next key event will be the FDA’s formal decision on the Galleri test. Retail traders on r/wallstreetbets have expressed optimism, calling the stock oversold ahead of the panel vote. Investors should also monitor coverage breadth, as the stock has drawn increased attention in the last 36 hours, with four stories from two sources.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.
GRAIL (GRAL) stock hits a 52-week high after an FDA advisory panel backs Galleri, a multi-cancer blood test developed by the company. Read more here.
A panel of US FDA advisors voted that there is reasonable evidence that GRAIL’s (GRAL) multi-cancer early detection blood test Galleri is effective. The vote wa
The stock has been on a trading halt on Wednesday ahead of the committee meeting, but it rallied 34% on Monday after the FDA posted briefing papers that flagged no particular concerns.
More on GRAL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GRAL move explainers: 2026-09-25 · 2026-09-24 · 2026-09-22 · 2026-09-21 · 2026-08-06